Search

Displaying results 1881 - 1890 of 10000 in total
  1. Drug

    Oxybutynin

    go.drugbank.com/drugs/DB01062
    ApprovedInvestigational

    It is often used as first-line therapy for OAB.[A185990] … efficacy since initial FDA approval in 1975.

    International brands: Lyrinel XLProducts: VOXET 5 MG /5 ML ŞURUP,100 ML, Ditropan XL
  2. Drug

    Mephenesin

    go.drugbank.com/drugs/DB13583
    ApprovedWithdrawn

    Mephenesin is a synthetic cresol glyceryl ether which produces transient muscle relaxation and paralysis via central nervous system depression [A32760]. It first entered use in the 1950s.

  3. Drug

    Iobenguane sulfate I-123

    go.drugbank.com/drugs/DB09546
    Approved

    Iobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

    Synonyms: Iobenguane sulfate I 123, Iobenguane sulfate I-123Products: i 123 MIBG meta iodobenzylguanidine
  4. Drug

    Elamipretide

    go.drugbank.com/drugs/DB11981
    ApprovedInvestigational

    [L54036] In September 2025, the U.S. … [A274436] Elamipretide is a synthetic tetrapeptide that selectively binds to cardiolipin, a phospholipid in the inner mitochondrial membrane.

  5. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    [L43277] Niraparib is selective towards PARP-1 and PARP-2. … Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.

  6. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [L51973] When administered alongside glucocorticoid replacement in patients with CAH it allows for the use of lower, physiological doses for glucocorticoid replacement, thereby reducing the risks associated

  7. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    ; Both biosimilars also received marketing authorization in the EU in May 2024. … It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.

    Products: XGEVA® 120 MG/1.7 ML, Prolia Solution for Injection 60 mg/ml (Prefilled Syringe)
  8. Drug

    Fluoroestradiol F-18

    go.drugbank.com/drugs/DB15690
    ApprovedInvestigational

    [L14117] It is expected to be available in late 2020/early 2021.[L14117] … [L14096] The ability to image ER-positive tumors _in vivo_ is advantageous in that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression

  9. Drug

    Influenza B virus B/Massachusetts/2/2012 BX-51B hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14397
    Approved

    that it was previously exposed to. … The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses.

    Mixtures: FluVaccinol Subunit Tetra Injektionssuspension in einer Fertigspritze
  10. Drug

    Droperidol

    go.drugbank.com/drugs/DB00450
    ApprovedInvestigationalVet approved

    It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the … It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)

    Synonyms: 1-{1-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-1,2,3,6-tetrahydro-pyridin-4-yl}-1,3-dihydro-benzoimidazol-2-oneProducts: Inapsine Inj 2.5mg/ml, Xomolix 2,5 mg/ml Injektionslösung